NAD+observational1990

Photolabelling of mutant forms of the S1 subunit of pertussis toxin with NAD+.

The Biochemical journal

confidence

Key findings

Photolabelling of S1 subunit with NAD+ correlated with NAD+ glycohydrolase activity; N-terminal region implicated in NAD+ binding.

View source on PubMed (PMID 2363691) ↗

Sample size
Not reported
Population
In vitro recombinant-derived S1 subunit mutants of pertussis toxin
Dosing
Radiolabelled NAD+ photolabelling
Duration
Not reported
Route
In vitro
Blinding
not_reported
Controls
none
Drug class
coenzyme
Full abstract

The S1 subunit of pertussis toxin catalyses the hydrolysis of NAD+ (NAD+ glycohydrolysis) and the NAD(+)-dependent ADP-ribosylation of guanine-nucleotide-binding proteins. Recently, the S1 subunit of pertussis toxin was shown to be photolabelled by using radiolabelled NAD+ and u.v.; the primary labelled residue was Glu-129, thereby implicating this residue in the binding of NAD+. Studies from various laboratories have shown that the N-terminal portion of the S1 subunit, which shows sequence similarity to cholera toxin and Escherichia coli heat-labile toxin, is important to the maintenance of both glycohydrolase and transferase activity. In the present study the photolabelling technique was applied to the analysis of a series of recombinant-derived S1 molecules that possessed deletions or substitutions near the N-terminus of the S1 molecule. The results revealed a positive correlation between the extent of photolabelling with NAD+ and the magnitude of specific NAD+ glycohydrolase activity exhibited by the mutants. Enzyme kinetic analyses of the N-terminal mutants also identified a mutant with substantially reduced activity, a depressed photolabelling efficiency and a markedly increased Km for NAD+. The results support a direct role for the N-terminal region of the S1 subunit in the binding of NAD+, thereby providing a rationale for the effect of mutations in this region on enzymic activity.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.